- Home
- GLO vs FENC Comparison
GLO vs FENC Comparison
Compare GLO & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLO
- FENC
- Stock Information
- Founded
- GLO 2006
- FENC 1996
- Country
- GLO United States
- FENC United States
- Employees
- GLO N/A
- FENC N/A
- Industry
- GLO Finance/Investors Services
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLO Finance
- FENC Health Care
- Exchange
- GLO Nasdaq
- FENC Nasdaq
- Market Cap
- GLO 242.5M
- FENC 225.4M
- IPO Year
- GLO N/A
- FENC 2001
- Fundamental
- Price
- GLO $5.73
- FENC $9.47
- Analyst Decision
- GLO
- FENC Strong Buy
- Analyst Count
- GLO 0
- FENC 2
- Target Price
- GLO N/A
- FENC $13.50
- AVG Volume (30 Days)
- GLO 170.5K
- FENC 90.6K
- Earning Date
- GLO 01-01-0001
- FENC 11-06-2025
- Dividend Yield
- GLO 11.38%
- FENC N/A
- EPS Growth
- GLO N/A
- FENC N/A
- EPS
- GLO N/A
- FENC N/A
- Revenue
- GLO N/A
- FENC $33,302,000.00
- Revenue This Year
- GLO N/A
- FENC $0.18
- Revenue Next Year
- GLO N/A
- FENC $52.59
- P/E Ratio
- GLO N/A
- FENC N/A
- Revenue Growth
- GLO N/A
- FENC N/A
- 52 Week Low
- GLO $4.08
- FENC $3.96
- 52 Week High
- GLO $5.18
- FENC $9.92
- Technical
- Relative Strength Index (RSI)
- GLO 60.20
- FENC 58.05
- Support Level
- GLO $5.66
- FENC $8.26
- Resistance Level
- GLO $5.77
- FENC $9.92
- Average True Range (ATR)
- GLO 0.05
- FENC 0.39
- MACD
- GLO -0.00
- FENC 0.08
- Stochastic Oscillator
- GLO 62.76
- FENC 75.39
About GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.